Research programme: engineered regulatory T-cell therapeutics - GentiBio/Bristol Myers Squibb
Latest Information Update: 30 Aug 2022
At a glance
- Originator GentiBio
- Developer Bristol-Myers Squibb; GentiBio
- Class Gene therapies; Regulatory T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Inflammatory bowel diseases